Skip to main content
Top
Published in: Breast Cancer 2/2008

01-04-2008 | Original Article

Screening ultrasonography revealed 15% of mammographically occult breast cancers

Authors: Ken Uchida, Akinori Yamashita, Kazumi Kawase, Kentarou Kamiya

Published in: Breast Cancer | Issue 2/2008

Login to get access

Abstract

Background

Mammography and physical examination (PE) are the recommended modalities for breast-cancer screening for women 40 years and older in Japan. Mammography, however, cannot detect lesions in dense breast tissue, which is common in Japanese women. Breast screening by ultrasound (US) is popular in Japan. We studied which modality or combinations of modalities optimize breast cancer detection for Japanese women.

Methods

From April 1993 through March 2005 we found 97 breast cancers in 9,082 women by screening examinations with mammography, US, and PE. We compared the detection rates of these three modalities for breast cancer.

Results

The detection rates of mammography, US, and PE for breast cancer were 83.5 (81 of 97 cancers), 75.3 (73 of 97 cancers), and 60.8% (59 of 97 cancers), respectively. The detection rates of the combinations of mammography and US, mammography and PE, and US and PE were 99.0 (96 of 97 cancers), 88.7 (86 of 97 cancers), and 81.4% (79 of 97 cancers), respectively. Ultrasonography detected 15% of the mammographically occult breast cancers.

Conclusion

Screening with the combination of mammography and US significantly increases the detection rate of breast cancer. These results suggest that screening with mammography and US would optimize cancer detection in Japanese women.
Literature
1.
go back to reference Mammography Guidelines, 2nd ed. Tokyo: Igakushoin; 2004. Mammography Guidelines, 2nd ed. Tokyo: Igakushoin; 2004.
2.
go back to reference Kerlikowske K, Grady D, Rubin SM, Sandrock C, Emster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149–54.PubMedCrossRef Kerlikowske K, Grady D, Rubin SM, Sandrock C, Emster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149–54.PubMedCrossRef
3.
go back to reference Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2001;225(1):165–75.CrossRef Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2001;225(1):165–75.CrossRef
5.
go back to reference Tarter PI, Weiss S, Armed S, Kamath S, Hermann G, Drossman S. Mammographically occult breast cancers. Breast J. 1999;5(1):22–5.CrossRef Tarter PI, Weiss S, Armed S, Kamath S, Hermann G, Drossman S. Mammographically occult breast cancers. Breast J. 1999;5(1):22–5.CrossRef
6.
go back to reference Namba K, Watanabe R, Furusawa H, Matsu T, Shirouzu M, Tanaka C, Hirokaga K, Masuda T, Takahashi M, Namba S. Significance of breast cancer screening by mammography and ultrasound for women aged 49 and under. J Jpn Assoc Breast Cancer Screen. 2002;11(2):172–7. Namba K, Watanabe R, Furusawa H, Matsu T, Shirouzu M, Tanaka C, Hirokaga K, Masuda T, Takahashi M, Namba S. Significance of breast cancer screening by mammography and ultrasound for women aged 49 and under. J Jpn Assoc Breast Cancer Screen. 2002;11(2):172–7.
7.
go back to reference Takahashi K, Nishimura S, Tanaka K, Higa J, Makita M, Yoshimoto M, Kasumi F, Sakuma H, Akiyama F, Sakamoto G. Role of mammography and ultrasound in breast cancer screening for women in their 40s. Jpn Assoc Breast Cancer Screen. 2002;11(3):341. Takahashi K, Nishimura S, Tanaka K, Higa J, Makita M, Yoshimoto M, Kasumi F, Sakuma H, Akiyama F, Sakamoto G. Role of mammography and ultrasound in breast cancer screening for women in their 40s. Jpn Assoc Breast Cancer Screen. 2002;11(3):341.
8.
go back to reference Ma L, Fishell E, Wright B, Hanna W, Allan S, Bovd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst. 1992;84(10):781–5.PubMedCrossRef Ma L, Fishell E, Wright B, Hanna W, Allan S, Bovd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst. 1992;84(10):781–5.PubMedCrossRef
9.
go back to reference Tohno E, Ueno E. Ultrasound (US) diagnosis of nonpalpable breast cancer. Breast Cancer. 2005;12(4):267–71.PubMedCrossRef Tohno E, Ueno E. Ultrasound (US) diagnosis of nonpalpable breast cancer. Breast Cancer. 2005;12(4):267–71.PubMedCrossRef
10.
go back to reference Gordon PB, Goldenberg AL. Malignant breast masses detected only by ultrasound. A retrospective review. Cancer. 1995;76(4):626–30.PubMedCrossRef Gordon PB, Goldenberg AL. Malignant breast masses detected only by ultrasound. A retrospective review. Cancer. 1995;76(4):626–30.PubMedCrossRef
11.
go back to reference Buchberger W, Niehoff A, Obrist P, Dekoekkoek-Doll P, Duncer M. Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR. 2000;21(4):325–36.PubMedCrossRef Buchberger W, Niehoff A, Obrist P, Dekoekkoek-Doll P, Duncer M. Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR. 2000;21(4):325–36.PubMedCrossRef
Metadata
Title
Screening ultrasonography revealed 15% of mammographically occult breast cancers
Authors
Ken Uchida
Akinori Yamashita
Kazumi Kawase
Kentarou Kamiya
Publication date
01-04-2008
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2008
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-007-0024-x

Other articles of this Issue 2/2008

Breast Cancer 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine